Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announces significant senior executive hires to further expand services for Novotech’s global biotech clients.
Rick Farris, a seasoned professional in the clinical research and life sciences industry, has taken on the role of Managing Director for North America which includes teams in San Francisco, Boston, Boulder, and Charleston with further expansions underway.
Dr. David Ng a specialist in biostatistics and biometrics has assumed the position of Global Vice President for Biometrics and Data Management.
Novotech’s CEO Dr. John Moller expressed his enthusiasm, stating, “I am pleased to extend a warm welcome to both Rick Farris and Dr. David Ng as they join the Novotech family. Their wealth of experience, proven expertise, and unwavering dedication to excellence in the clinical research and life sciences sector make them invaluable additions to our team. We are confident that their leadership and contributions will drive Novotech's continued growth and success.”
“Rick's extensive background, with 22 years in biotech clinical research and drug development, complemented by over 30 years in the life sciences, makes him exceptionally qualified for this critical leadership role within our North American operations,” stated Dr. Moller.
Dr. Moller highlighted Rick's substantial executive expertise, which encompasses a history with global CROs such as IQVIA. “Rick has led operations teams and played a key role in establishing global project management capabilities. His CRO background is diverse, including business development, client relations management, process reengineering, and consulting, with a specific focus on supporting biotech companies in bringing innovative drugs to market. Additionally, his areas of therapeutic expertise span reproductive health, oncology, diagnostic devices, and rare diseases."
“I am very excited to join Novotech, a CRO I have successfully partnered with in the past on large global programs. Novotech’s approach to client partnership and biotech focus is very appealing to me. I am joining at an exciting time, where Novotech is further expanding the North America operations to serve the innovative biotech market,” commented Rick.
Dr. David Ng’s appointment as Novotech’s Global VP of Biometrics and Data Management brings over three decades of biostatistics, data management, and strategic leadership. “He will lead a team of 350+ data managers in charge of helping sponsors with study design and statistical strategy,” remarked Dr. Moller.
Most recently Dr. Ng served as VP of Biometrics for WuXi Clinical, a subsidiary of WuXi AppTec. He also previously held senior and executive level roles at PPD, a division of Thermo Fisher Scientific. “His extensive track record will further expand our biostatistics services, from first-in-man to Phase IV trials, across a broad range of therapeutic areas,” indicated Dr. Moller.
“The landscape of clinical trial designs is growing increasingly intricate, prompting biotech companies to seek more scalable solutions, particularly in the field of data quality and biometrics. I am very pleased to be taking on this important role at such an exciting time in Novotech’s global growth program. The biometrics team is exceptional, and I look forward to expanding our presence and capabilities to further support our biotech clients,” stated Dr. Ng.
Novotech has more than 3,000 employees operating across 25 geographies with 34 office locations, including Greater China, South Korea, Australia, New Zealand, the US, and Europe.
The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023 and the Best Cell & Gene Therapy CRO 2022 and 2023 awards. Additionally, the company was honored with the Asia-Pacific Contract Research Organization Company of the Year Award in 2023. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is internationally recognized as the leading Asia Pacific centred Contract Research Organization (CRO) with global execution capabilities.
The Company has established itself as a clinical CRO with labs, phase I facilities, drug development consulting services and regulatory expertise. It has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech employs over 3,000 staff globally across 34 office locations.
Novotech is positioned to serve as a partner and ally to small and medium-sized biotech, biopharma and pharma sponsors seeking to conduct clinical trials in Asia Pacific, the US and Europe.
For more information visit Novotech CRO
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer30.11.2023 21:00:00 CET | pressemeddelelse
KØBENHAVN, Danmark, 30. november 2023 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnHenrik Juuel2.Årsag til indberetningena)Stilling/titelExecutive Vice President og Chief Financial Officer i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen Ident
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such30.11.2023 21:00:00 CET | Press release
COPENHAGEN, Denmark, November 30, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NameHenrik Juuel2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Financial Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeS
BW Ideol AS – End of Offer Period for the recommended voluntary offer by BW Sirocco Holdings AS, and final level of acceptances of the offer30.11.2023 19:51:43 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES Oslo, 30 November 2023 - Reference is made to the announcement made by BW Sirocco Holdings AS (the "Offeror) on 9 November 2023 regarding a recommended voluntary offer to acquire all the issued and outstanding shares (the "Shares") in BW Ideol AS ("BW Ideol" or the "Company"), not already held by the Initiating Shareholders (as defined in the Offer Document), at an offer price of NOK 12 per Share (the "Offer Price"), to be settled in cash or shares in the Offeror (the "Offer"), as further described in the combined offer document and national prospectus (the "Offer Document"), the announcement on 14 November regarding the publication of the Offer Document and commencement of
Ensurge Micropower ASA - Approval and publication of prospectus; commencement of subscription period in Subsequent Offering30.11.2023 19:32:57 CET | Press release
Reference is made to the stock exchange announcement published on 18 October 2023 by Ensurge Micropower ASA ("Ensurge" or the "Company"), regarding the successful placement of new shares, through an allocation of 122,846,875 new shares in Tranche 1 (the "Tranche 1 Shares") and an allocation of 352,153,125 new shares in Tranche 2 (the "Tranche 2 Shares"), as well as a possible subsequent repair offering raising up to NOK 12.5 million through the offering of up to 125,000,000 shares (the "Offer Shares") on similar terms as the private placement (the "Subsequent Offering"). As stated in the stock exchange announcement on 18 October 2023, the Subsequent Offering and the trading of the Tranche 2 Shares remained subject to approval of a prospectus by the Financial Supervisory Authority of Norway. Further reference is made to the Extraordinary General Meeting held on 10 November 2023 approving the issuance of the Tranche 2 Shares and the Subsequent Offering. The Financial Supervisory Authorit
Acronis Named a Leader in the IDC MarketScape: Worldwide Cyber-Recovery 2023 Vendor Assessment30.11.2023 18:59:51 CET | Press release
BURLINGTON, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Acronis, the global leader in cyber protection, today announced it had been identified as a Leader in the IDC MarketScape: Worldwide Cyber Recovery 2023 Vendor Assessment (doc #US49787923, November 2023). This is the first IDC MarketScape report about cyber recovery which illustrates the growing importance of both proactive defense and reactive recovery within an organization’s ability to deal with cyberattacks. The IDC MarketScape report cites Acronis’ key offerings, including a single agent that simplifies deployment and enables unique integration capabilities as well as integrated end-point protection. “Acronis was one of the first data protection vendors to identify and target the cyber recovery marketplace nearly five years ago and to rearchitect their solution specifically for cyber recovery,” the IDC MarketScape noted. Additionally, when referencing the company’s fundraising efforts in the past couple of years, the IDC MarketS